Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

While both drugs have demonstrated significant weight-loss effects in previous trials ... tolerated dose of tirzepatide (10 or 15 mg; n = 374) or semaglutide (1.7 or 2.4 mg; n = 376) once weekly ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...